Xsensio, a portfolio company, has raised an oversubscribed $7 million Series A round led by WI Harper. The round also saw participation from Privilège Ventures, the European Innovation Council, and international private investors.
This funding marks a key step forward in Xsensio’s mission to enable continuous biochemical monitoring in healthcare.
At the center of this innovation is LabonSkin®, Xsensio’s wearable biosensing platform. It allows clinicians to access near real-time biochemical data—something that has traditionally been unavailable at the point of care. As a result, healthcare providers can make faster, more informed decisions for patients.
Continuous biochemical monitoring has long been a missing piece in modern healthcare. Xsensio is addressing this gap by turning complex lab measurements into continuous, wearable insights. This shift has the potential to improve patient outcomes across hospitals, remote care, and chronic disease management.
Alongside the funding, Xsensio also announced a long-term collaboration with Texas Instruments. This partnership will support scalable semiconductor integration, helping bring its technology to a broader market.
Xsensio’s progress highlights the impact of early-stage investing in deep tech and digital health. With strong investor backing and strategic partnerships, the company is well-positioned to lead the future of wearable healthcare technology.
